表纸
市场调查报告书

B型血友病:开发中产品分析

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品编码 232835
出版日期 内容资讯 英文 150 Pages
订单完成后即时交付
价格
B型血友病:开发中产品分析 Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020
出版日期: 2020年03月31日内容资讯: 英文 150 Pages
简介

B型血友病,是由于血液凝固第九凝血因子的不足而产生,遗传性的出血疾病。若没有充分数量的第九凝血因子,无法使血液凝固有效堵住出血。主要症状,有在关节内部的出血,伴随关节痛、肿胀,紫斑,环状切除伴随的过剩出血,消化管、尿路的出血,鼻血等。主要的治疗方法,有缺损的凝血因子的补充等。

本报告提供全球各国的B型血友病治疗用的开发中产品的开发情形相关分析,产品开发、上市的最新趋势,及临床实验的各阶段的产品一览,主要企业简介,主要药物概要,最新的产业趋势等资讯,为您概述为以下内容。

目录

简介

  • 分析范围

B型血友病概要

治疗药的开发

  • B型血友病开发中产品:概要
  • B型血友病开发中产品:各企业
  • B型血友病开发中产品:各大学/研究机关
  • B型血友病治疗药:开发中的产品一览:各企业
  • B型血友病治疗药:各研究中的产品一览:各大学/研究机关

B型血友病:治疗药的评估

  • 各标的
  • 各作用机制
  • 各投药法
  • 各分子类型

B型血友病开发治疗药的企业

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Bayer AG
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • China Biologic Products Inc
  • CSL Ltd
  • Genethon SA
  • Green Cross Corp
  • LFB SA
  • MolMed SpA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Spark Therapeutics Inc
  • UniQure NV

药物简介

B型血友病治疗药:开发暂停的产品

B型血友病治疗药:开发中止的产品

B型血友病相关产品的开发里程碑

  • 值得注意的最新趋势、新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC12079IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 6, 2, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
    • Hemophilia B (Factor IX Deficiency) - Overview
    • Hemophilia B (Factor IX Deficiency) - Therapeutics Development
    • Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment
    • Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics Development
    • Hemophilia B (Factor IX Deficiency) - Drug Profiles
    • Hemophilia B (Factor IX Deficiency) - Dormant Projects
    • Hemophilia B (Factor IX Deficiency) - Discontinued Products
    • Hemophilia B (Factor IX Deficiency) - Product Development Milestones
    • Appendix

List of Tables

  • Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by China Biologic Products Holdings Inc, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020
  • Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Hemophilia B (Factor IX Deficiency) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020